Clinical trials: Diabete Type 2
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control…
- Trial name
- SUSTAIN (NCT03061214)
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin
- Where
- 67 sites in Brazil, China and 5 more
- Volunteers
- 868 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under…
- Trial name
- NCT02321878
- Testing
- liraglutide
- Where
- 5 sites in Japan
- Volunteers
- 1,092 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes Mellitus
Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.
The purpose of this study is to evaluate the efficacy and safety of Lima association in the control of type 2 diabetes mellitus
- Trial name
- NCT03766750
- Testing
- LIMA association, Tradjenta, Forxiga
- Sponsor
- EMS
Type 2 Diabetes
Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
SP2086 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have…
- Trial name
- NCT01969318
- Testing
- SP2086(50 mg q.d.)/Metformin, SP2086 (100 mg q.d.)/Metformin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.
- Trial name
- REGENT-1 (NCT04725890)
- Testing
- The DyaMX Device
- Where
- 2 sites in Australia
- Volunteers
- 65 people
- Sponsor
- Endogenex, Inc.
Diabetes Mellitus, Type 2
OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
This is an open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of OXEMET™ 1000 mg coated tablets, relative to 1000 mg of the reference product administered as two 500 mg tablets, under…
- Trial name
- NCT01842620
- Testing
- Metformin
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.
- Trial name
- NCT00485758
- Testing
- ER niacin/laropiprant
- Volunteers
- 796 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of HS-20094 in Healthy Participants
This study includes two parts (Single Ascending Dose, SAD; Multiple-Ascending Dose, MAD) and enrolls healthy participants. Participants in SAD accept single subcutaneous (SC) injection of HS-20094 and participants in MAD accept…
- Trial name
- NCT05116410
- Testing
- HS-20094
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions
This study was open-label, randomized, fed, single-dose, 2-groups, 2 periods, crossover designe to compare the safety and pharmacokinetics of UI068 and co-administration of UIC202205 and UIC202206.
- Trial name
- NCT06141590
- Testing
- administration of UI068, administration of UIC202205, UIC202206
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Diabetes Mellitus, Type 2, Renal Disease
A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases
- Conditions
- Diabetes Mellitus, Type 2, Renal Disease, Diabetes Mellitus, Metabolic Disease
- Trial name
- NCT04653779
- Testing
- Evogliptin 5mg/Metformin 1000mg
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the…
- Trial name
- NCT03292185
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01792635
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Type 2 Diabetes
A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes
A Phase 1, combined Single Ascending Dose (SAD) and Multiple-ascending Dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MEDI4166 in Subjects with Type 2 Diabetes Mellitus…
- Trial name
- NCT02524782
- Testing
- MEDI-4166
- Where
- 11 sites in United States
- Volunteers
- 103 people
- Sponsor
- MedImmune LLC
Diabetes, Diabetes Mellitus, Type 2
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).
- Trial name
- NCT01403025
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 4,121 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
- Trial name
- NCT01285518
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.
- Trial name
- NCT02077946
- Testing
- liraglutide, sitagliptin
- Where
- Sweden
- Volunteers
- 1,059 people
- Sponsor
- Novo Nordisk A/S